Literature DB >> 26891149

Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.

Thomas Wilhelm1, Daniel B Lipka2, Tania Witte1, Justyna A Wierzbinska1,2, Silvia Fluhr3,4, Monika Helf2, Oliver Mücke1,2, Rainer Claus1,5, Carolin Konermann1, Peter Nöllke3, Charlotte M Niemeyer3,6, Christian Flotho3,6, Christoph Plass1,6.   

Abstract

A-kinase anchor protein 12 (AKAP12) is a regulator of protein kinase A and protein kinase C signaling, acting downstream of RAS. Epigenetic silencing of AKAP12 has been demonstrated in different cancer entities and this has been linked to the process of tumorigenesis. Here, we used quantitative high-resolution DNA methylation measurement by MassARRAY to investigate epigenetic regulation of all three AKAP12 promoters (i.e., α, β, and γ) within a large cohort of juvenile myelomonocytic leukemia (JMML) patient samples. The AKAP12α promoter shows DNA hypermethylation in JMML samples, which is associated with decreased AKAP12α expression. Promoter methylation of AKAP12α correlates with older age at diagnosis, elevated levels of fetal hemoglobin and poor prognosis. In silico screening for transcription factor binding motifs around the sites of most pronounced methylation changes in the AKAP12α promoter revealed highly significant scores for GATA-2/-1 sequence motifs. Both transcription factors are known to be involved in the haematopoietic differentiation process. Methylation of a reporter construct containing this region resulted in strong suppression of AKAP12 promoter activity, suggesting that DNA methylation might be involved in the aberrant silencing of the AKAP12 promoter in JMML. Exposure to DNMT- and HDAC-inhibitors reactivates AKAP12α expression in vitro, which could potentially be a mechanism underlying clinical treatment responses upon demethylating therapy. Together, these data provide evidence for epigenetic silencing of AKAP12α in JMML and further emphasize the importance of dysregulated RAS signaling in JMML pathogenesis.

Entities:  

Keywords:  AKAP12; Azacytidine; DNA methylation; Epigenetics; Hematopoiesis; Juvenile myelomonocytic leukemia; Leukemia

Mesh:

Substances:

Year:  2016        PMID: 26891149      PMCID: PMC4846096          DOI: 10.1080/15592294.2016.1145327

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  39 in total

Review 1.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

Authors:  C M Niemeyer; M Arico; G Basso; A Biondi; A Cantu Rajnoldi; U Creutzig; O Haas; J Harbott; H Hasle; G Kerndrup; F Locatelli; G Mann; B Stollmann-Gibbels; E T van't Veer-Korthof; E van Wering; M Zimmermann
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

2.  SSeCKS gene expression in vascular smooth muscle cells: regulation by angiotensin II and a potential role in the regulation of PAI-1 gene expression.

Authors:  S R Coats; J W Covington; M Su; L M Pabón-Peña; M Eren; Q Hao; D E Vaughan
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

3.  Gene trap insertion reveals two open reading frames in the mouse SSeCKS gene: the form predominantly detected in the nervous system is suppressed by the insertion while the other, specific of the testis, remains expressed.

Authors:  A Camus; K Mesbah; M Rallu; C Babinet; J Barra
Journal:  Mech Dev       Date:  2001-07       Impact factor: 1.882

4.  A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer.

Authors:  Yuriko Mori; Kun Cai; Yulan Cheng; Suna Wang; Bogdan Paun; James P Hamilton; Zhe Jin; Fumiaki Sato; Agnes T Berki; Takatsugu Kan; Tetsuo Ito; Carmit Mantzur; John M Abraham; Stephen J Meltzer
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

5.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

6.  RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML).

Authors:  C Flotho; S Valcamonica; S Mach-Pascual; G Schmahl; L Corral; J Ritterbach; H Hasle; M Aricò; A Biondi; C M Niemeyer
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

Review 7.  Gene silencing by DNA methylation in haematological malignancies.

Authors:  Jacqueline Boultwood; James S Wainscoat
Journal:  Br J Haematol       Date:  2007-05-09       Impact factor: 6.998

8.  Going with the flow: JAK-STAT signaling in JMML.

Authors:  Demetrios Kalaitzidis; D Gary Gilliland
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

9.  AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies.

Authors:  Christian Flotho; Annika Paulun; Christiane Batz; Charlotte M Niemeyer
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

10.  The angiogenesis suppressor gene AKAP12 is under the epigenetic control of HDAC7 in endothelial cells.

Authors:  Andrei Turtoi; Denis Mottet; Nicolas Matheus; Bruno Dumont; Paul Peixoto; Vincent Hennequière; Christophe Deroanne; Alain Colige; Edwin De Pauw; Akeila Bellahcène; Vincent Castronovo
Journal:  Angiogenesis       Date:  2012-05-15       Impact factor: 9.596

View more
  13 in total

Review 1.  Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.

Authors:  Christian Flotho
Journal:  Epigenetics       Date:  2019-03-08       Impact factor: 4.528

2.  Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the β-like globin locus in juvenile myelomonocytic leukemia.

Authors:  Silvia Fluhr; Christopher Felix Krombholz; Angelina Meier; Thomas Epting; Oliver Mücke; Christoph Plass; Charlotte M Niemeyer; Christian Flotho
Journal:  Epigenetics       Date:  2017-07-27       Impact factor: 4.528

Review 3.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

4.  Development and Validation of a Prognostic Nomogram Based on DNA Methylation-Driven Genes for Patients With Ovarian Cancer.

Authors:  Min Zhou; Shasha Hong; Bingshu Li; Cheng Liu; Ming Hu; Jie Min; Jianming Tang; Li Hong
Journal:  Front Genet       Date:  2021-09-09       Impact factor: 4.772

5.  International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.

Authors:  Maximilian Schönung; Julia Meyer; Hideki Muramatsu; Christian Flotho; Elliot Stieglitz; Daniel B Lipka; Peter Nöllke; Adam B Olshen; Mark Hartmann; Norihiro Murakami; Manabu Wakamatsu; Yusuke Okuno; Christoph Plass; Mignon L Loh; Charlotte M Niemeyer
Journal:  Clin Cancer Res       Date:  2020-11-02       Impact factor: 13.801

6.  CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.

Authors:  Christoph Plass; Christian Flotho; Silvia Fluhr; Melanie Boerries; Hauke Busch; Aikaterini Symeonidi; Tania Witte; Daniel B Lipka; Oliver Mücke; Peter Nöllke; Christopher Felix Krombholz; Charlotte M Niemeyer
Journal:  Clin Epigenetics       Date:  2016-05-05       Impact factor: 6.551

7.  Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation.

Authors:  Zheng Peng; Wenjun Zhou; Chun Zhang; Huining Liu; Yi Zhang
Journal:  Med Sci Monit       Date:  2018-01-24

8.  RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.

Authors:  Daniel B Lipka; Tania Witte; Reka Toth; Jing Yang; Manuel Wiesenfarth; Peter Nöllke; Alexandra Fischer; David Brocks; Zuguang Gu; Jeongbin Park; Brigitte Strahm; Marcin Wlodarski; Ayami Yoshimi; Rainer Claus; Michael Lübbert; Hauke Busch; Melanie Boerries; Mark Hartmann; Maximilian Schönung; Umut Kilik; Jens Langstein; Justyna A Wierzbinska; Caroline Pabst; Swati Garg; Albert Catalá; Barbara De Moerloose; Michael Dworzak; Henrik Hasle; Franco Locatelli; Riccardo Masetti; Markus Schmugge; Owen Smith; Jan Stary; Marek Ussowicz; Marry M van den Heuvel-Eibrink; Yassen Assenov; Matthias Schlesner; Charlotte Niemeyer; Christian Flotho; Christoph Plass
Journal:  Nat Commun       Date:  2017-12-19       Impact factor: 14.919

9.  ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end-stage heart failure patients.

Authors:  Ana Ortega; Estefanía Tarazón; Carolina Gil-Cayuela; Luis Martínez-Dolz; Francisca Lago; José Ramón González-Juanatey; Juan Sandoval; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera
Journal:  ESC Heart Fail       Date:  2018-04-17

10.  Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia.

Authors:  Andra Marcu; Andrei Colita; Letitia Elena Radu; Cristina Georgiana Jercan; Ana Maria Bica; Minodora Asan; Daniel Coriu; Alina Daniela Tanase; Carmen C Diaconu; Cristina Mambet; Anca Botezatu; Sergiu Pasca; Patric Teodorescu; Gabriela Anton; Petruta Gurban; Anca Colita
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.